Valuation: MiNK Therapeutics, Inc.

Market Cap 55.11M 49.45M 45.72M 41.4M 77.35M 5.25B 78.29M 547M 218M 2.75B 207M 202M 8.72B P/E 2026 *
-4.9x
P/E 2027 * -4.93x
Enterprise Value 55.11M 49.45M 45.72M 41.4M 77.35M 5.25B 78.29M 547M 218M 2.75B 207M 202M 8.72B EV / Sales 2026 *
29x
EV / Sales 2027 * 20x
Free-Float
40.31%
Yield 2026 *
-
Yield 2027 * -
1 day-1.11%
1 week+6.16%
Current month-14.90%
1 month-12.89%
3 months+2.89%
6 months-9.57%
Current year-4.22%
1 week 10.18
Extreme 10.18
11.68
1 month 9.19
Extreme 9.19
12.98
Current year 8.48
Extreme 8.4801
16.93
1 year 8.48
Extreme 8.4801
16.93
3 years 4.56
Extreme 4.5601
76
5 years 4.56
Extreme 4.5601
221.55
10 years 4.56
Extreme 4.5601
221.55
Manager TitleAgeSince
Chief Executive Officer 52 01/02/2021
Director of Finance/CFO 37 13/03/2026
Comptroller/Controller/Auditor 37 13/03/2026
Director TitleAgeSince
Director/Board Member 52 01/02/2021
Chairman 73 01/07/2017
Director/Board Member 62 01/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
12/10/26 Sell

Chief Executive Officer

-6,938 0.1360%
01/09/26 Free

Director

1,622 0.0318%
01/09/26 Free

Director

1,279 0.0251%
Change 5-day change 1-year change 3-year change Capi.($)
-1.30%+6.16%-23.77%+8.99% 55.11M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.75%+2.01%+13.30%+105.71% 53.03B
-0.67%-0.45%+27.19%+56.39% 45.99B
-0.47%-2.72%+18.11%+99.28% 42.45B
+0.48%+1.08%+226.97%+933.84% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.40%+3.61%+44.87%+147.90% 39.26B
Weighted average by Cap. -0.06%+3.13%+49.57%+160.97%

Financials

2026 *2027 *
Net sales 1.9M 1.7M 1.58M 1.43M 2.67M 181M 2.7M 18.84M 7.51M 94.69M 7.13M 6.98M 301M 2.75M 2.47M 2.28M 2.07M 3.86M 262M 3.91M 27.27M 10.86M 137M 10.32M 10.1M 435M
Net income -11.22M -10.06M -9.3M -8.43M -15.74M -1.07B -15.93M -111M -44.31M -559M -42.09M -41.2M -1.77B -16.05M -14.4M -13.31M -12.06M -22.53M -1.53B -22.8M -159M -63.4M -800M -60.23M -58.95M -2.54B
Net Debt - -
Projected Income Statement - Annual - MiNK Therapeutics, Inc.
Logo MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It is advancing a pipeline of both native and engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. Its advanced product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy designed to provide transformative treatment options. AgenT-797 is an iNKT cell therapy that harnesses the dual power of innate and adaptive immunity. In addition, it is advancing a pipeline of allogeneic, engineered iNKT programs. Its two advanced preclinical engineered programs are MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen (BCMA), and MiNK-215, an IL-15 armored tumor stromal targeting FAP-CAR-iNKT program.
Employees
15
Date Price Change Volume
29/10/26 $10.66 -1.30% 5,232
28/10/26 $10.80 +1.60% 6,133
27/10/26 $10.63 +1.92% 10,146
26/10/26 $10.43 -2.61% 13,320
23/10/26 $10.71 +6.46% 29,538
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - MiNK Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.80USD
Average target price
42.50USD
Spread / Average Target
+293.52%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - MiNK Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. INKT Stock